首页 > 市场调查报告书 > 医疗设备

伤口护理

市场调查报告书

商品编码

1623043

止血剂市场：依产品、形式、应用、最终用户、地区划分，2024-2031

Hemostats Market By Product, By Formulation, By Application, By End-User, And Region For 2024-2031

出版日期: 2024年08月27日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024-2031年止血材料市场评估

由于手术技术的进步、全球手术数量的增加、需要手术干预的慢性疾病盛行率的上升以及手术技术的技术进步，市场规模预计将在 2024 年超过 27 亿美元，预计将达到 27 亿美元。年为42.5 亿美元。

止血材料和技术的不断创新、新兴国家医疗保健成本的上升以及人口老化正在产生对更多外科手术的需求。因此，由于持续的技术创新，2024年至2031年市场将以5.81%的复合年增长率成长。

止血剂市场定义/概述

止血剂是一种医疗设备或药物，旨在控制外科手术或创伤期间的出血。这些产品透过促进血液凝固（凝血）或机械性密封血管以阻止血液流动来发挥作用。止血材料在一般外科、心血管外科、神经外科和急诊医学等多个医学领域中发挥重要作用。

此外，止血剂有多种形式，包括夹子和U形钉等机械止血剂，以及明胶海绵、氧化再生纤维素和胶原蛋白产品等可吸收和不可吸收材料。先进的止血材料还可以包含活性生物成分，例如凝血酶和纤维蛋白，以提高有效性。止血剂的选择取决于特定的手术程序、出血类型和严重程度以及患者因素。

先进止血技术对外科产业有何潜在影响？

先进的止血技术有望透过提高手术效率和病患治疗效果对外科手术产业产生重大影响。与传统方法相比，这些创新技术，例如基于奈米颗粒的止血剂和响应出血情况的智慧材料，有望缩短手术时间并最大限度地减少出血。透过为外科医生提供更精确、更快速的出血控制，这些技术使他们能够以更低的风险执行更复杂的手术，扩大可治疗疾病的范围，并消除具有课题性的手术程序，并可能提高成功率。

此外，先进的止血材料可以缩短患者的恢復时间并减少併发症，从而可能减少住院时间和医疗费用。这些技术与微创手术和机器人手术系统的整合也可以加速向微创手术的转变，透过更小的切口和更快的癒合使患者受益。这些先进止血材料的广泛采用可能会改变手术方案和培训，要求医疗保健专业人员掌握新技能，并改变手术专业。

医疗政策的改变将如何影响止血材料的采用？

医疗保健政策的变化可能会对止血材料的采用产生重大影响。随着世界各地的医疗保健系统越来越关注成本效益和患者结果，促进基于价值的医学的政策可能会加速先进止血材料的采用。儘管这些产品的初始成本较高，但它们可以透过减少手术併发症、缩短住院时间和改善患者復原时间来降低整体医疗成本。激励医院和外科医生提高效率和降低再入院率的政策可能会鼓励更多地使用有效的止血剂。

此外，旨在提高病人安全和减少术中不良事件的监管变化也可能支持采用更新、更有效的止血材料。简化创新医疗器械审批流程的政策，特别是那些满足外科护理关键需求的医疗器械，可以加速先进止血材料的市场进入。此外，扩大发展中国家手术机会的医疗改革可能会显着增加全球对止血材料的需求，因为它们需要提高手术能力和结果。

The advancements in surgical techniques, an increasing number of surgical procedures worldwide, and a rising prevalence of chronic diseases requiring surgical interventions. Thus, the technological advancements in surgical techniques surge the growth of market size surpassing USD 2.7 Billion in 2024 to reach the valuation of USD 4.25 Billion by 2031.

The ongoing innovations in hemostat materials and technologies, increasing healthcare expenditure in emerging economies, and a growing aging population require more surgical procedures. Thus, the ongoing innovations enable the market to grow at aCAGR of 5.81% from 2024 to 2031.

Hemostats Market: Definition/ Overview

Hemostats are medical devices or agents designed to control bleeding during surgical procedures or in cases of traumatic injury. These products work by promoting blood clotting (coagulation) or by mechanically sealing off blood vessels to stop blood flow. Hemostats play a crucial role in various medical fields, including general surgery, cardiovascular surgery, neurosurgery, and emergency medicine.

Furthermore, hemostats come in various forms, including mechanical devices like clips and staples, as well as absorbable and non-absorbable materials such as gelatin-based sponges, oxidized regenerated cellulose, and collagen-based products. Advanced hemostats may incorporate active biological components like thrombin or fibrin to enhance their effectiveness. The choice of hemostat depends on the specific surgical procedure, the type and severity of bleeding, and patient factors.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Potential Impacts of Advanced Hemostatic Technologies on the Surgical Industry?

Advanced hemostatic technologies are poised to significantly impact the surgical industry by enhancing procedural efficiency and patient outcomes. These innovations, including nanoparticle-based hemostats and smart materials that respond to bleeding conditions, promise to reduce surgical time and minimize blood loss more effectively than traditional methods. By providing surgeons with more precise and rapid bleeding control, these technologies could enable more complex procedures to be performed with reduced risk, potentially expanding the range of treatable conditions and improving success rates in challenging surgeries.

Furthermore, advanced hemostats could lead to shorter recovery times and reduced complications for patients, potentially decreasing hospital stays and healthcare costs. The integration of these technologies with minimally invasive and robotic surgical systems may also drive a shift towards less invasive procedures, benefiting patients through smaller incisions and faster healing. As these advanced hemostats become more widely adopted, they could reshape surgical protocols and training, necessitating new skills for healthcare professionals and potentially altering the landscape of surgical specialties.

How Will Changes in Healthcare Policies Affect the Adoption of Hemostatic Products?

Changes in healthcare policies are likely to have a significant impact on the adoption of hemostatic products. As healthcare systems worldwide increasingly focus on cost-effectiveness and patient outcomes, policies that promote value-based care may accelerate the adoption of advanced hemostats. These products, while potentially more expensive upfront, can reduce overall healthcare costs by decreasing surgical complications, shortening hospital stays, and improving patient recovery times. Policies that incentivize hospitals and surgeons to improve efficiency and reduce readmission rates may drive increased use of effective hemostatic solutions.

Furthermore, regulatory changes aimed at enhancing patient safety and reducing adverse events during surgeries could boost the adoption of newer, more effective hemostatic products. Policies that streamline the approval process for innovative medical devices, particularly those addressing critical needs in surgical care, may lead to faster market entry for advanced hemostats. Additionally, healthcare reforms that expand access to surgical procedures in developing countries could significantly increase the global demand for hemostatic products, as these nations seek to improve their surgical capabilities and outcomes.

Category-Wise Acumens

How does the Increasing Prevalence of Cardiovascular Diseases Surge the Growth of the Cardiovascular Surgery Segment?

The cardiovascular surgery segment dominates the hemostats market. Cardiovascular procedures, such as coronary artery bypass grafting and heart valve replacements, often involve complex manipulations of highly vascularized tissues, making effective bleeding control crucial. The increasing prevalence of cardiovascular diseases globally, coupled with advancements in cardiac surgical techniques, has led to a rise in the number of these procedures. This trend has created a substantial and growing demand for specialized hemostatic products that can address the unique challenges of cardiac surgeries, such as the need for rapid and durable hemostasis in a dynamic, high-pressure environment.

Furthermore, the critical nature of cardiovascular surgeries means that surgeons often prefer advanced hemostatic solutions that offer superior efficacy and reliability. This preference is driving innovation in the hemostat market, with manufacturers developing products specifically tailored for cardiovascular applications. These may include products with enhanced adhesive properties to withstand blood pressure or those that can be applied in minimally invasive cardiac procedures. As cardiovascular surgeries continue to evolve, becoming less invasive and more complex, the demand for sophisticated hemostats is expected to grow, further propelling the overall market expansion and shaping product development strategies in the industry.

How does the Increasing Frequency of Emergency Surgeries in Hospital Settings Surge the Growth of the Hospital Segment?

The hospital segment dominates the hemostats market driven by the increasing frequency of emergency surgeries in hospital settings, which is significantly boosting the hemostats market. As trauma cases, acute medical conditions, and unforeseen complications rise, hospitals face a growing need for rapid and effective bleeding control solutions. Emergency surgeries often involve critical situations where time is of the essence, and conventional hemostatic methods may be insufficient. This urgent demand drives the adoption of advanced hemostatic products that can quickly and reliably stop bleeding, even in challenging conditions. Consequently, hospitals invest in a diverse range of hemostats to ensure they are well-equipped to handle various emergencies.

Furthermore, the unpredictable nature of emergency surgeries necessitates that hospitals maintain a robust inventory of hemostatic products. This requirement leads to consistent and potentially increasing orders from hospital systems, providing a steady growth driver for the hemostats market. The emphasis on improving emergency care outcomes also encourages the development and adoption of innovative hemostatic technologies specifically designed for rapid deployment in high-pressure situations. As hospitals strive to enhance their emergency surgical capabilities, the demand for versatile, easy-to-use, and highly effective hemostats continues to grow, further stimulating market expansion and product innovation in the hemostats sector.

Country/Region-wise Acumens

What Role Do Regulatory Frameworks in North America Play in Shaping the Development of Hemostatic Products?

North America substantially dominates the hemostats market owing to the regulatory frameworks in North America, particularly those established by the U.S. Food and Drug Administration (FDA) and Health Canada, which play a crucial role in shaping the development of hemostatic products. These agencies set stringent standards for safety, efficacy, and quality, which directly influence product design, testing protocols, and manufacturing processes.

The FDA's premarket approval (PMA) process for Class III medical devices, which includes many advanced hemostatic products, requires extensive clinical trials and data submission. This rigorous approach drives manufacturers to invest heavily in research and development, leading to innovative products with demonstrated safety and effectiveness. Additionally, post-market surveillance requirements encourage ongoing refinement and improvement of hemostatic technologies, ensuring their continued safety and efficacy in real-world clinical settings. These regulatory frameworks ultimately foster a culture of continuous innovation while maintaining high standards for patient safety.

What Role Does the Expanding Medical Tourism Sector in Asia Pacific Play in Boosting the Demand for Hemostats?

Asia Pacific is anticipated to witness the fastest growth in the hemostats market during the forecast period owing to the growth of medical tourism has led to an increase in complex surgical procedures being performed in the region. Countries like Thailand, Singapore, and India have become popular destinations for a wide range of surgeries, from cosmetic procedures to organ transplants. This surge in surgical activity naturally drives up the demand for hemostatic products, which are essential for managing bleeding during and after operations. As these countries strive to offer world-class medical services, they are investing in advanced hemostatic technologies to ensure optimal patient outcomes and maintain their competitive edge in the global medical tourism market.

Furthermore, the medical tourism sector's emphasis on quality and patient safety has raised standards across the healthcare industry in Asia Pacific. To attract international patients, hospitals and clinics are adopting the latest medical technologies, including advanced hemostatic products. This trend is not limited to premier hospitals catering to medical tourists but is also influencing local healthcare providers who are upgrading their facilities and practices to compete. Consequently, the demand for high-quality hemostats is increasing across the broader healthcare landscape, driven by the ripple effect of medical tourism's quality standards.

Competitive Landscape

The Hemostats Market is exceptionally competitive, driven by product innovation, different formulations, and rising surgical demand. To increase market share, key players prioritize technical developments and global expansion.

Some of the prominent players operating in the hemostats market include:

CR Bard, Inc.

Braun Melsungen AG

Baxter International, Inc.

Integra LifeSciences

Marine Polymer Technologies, Inc.

Teleflex

Ethicon, Inc.

Pfizer, Inc.

Z-Medica LLC

Gelita Medical GmbH

Anika Therapeutics, Inc.

Stryker

Latest Developments

In March 2024, Baxter International announced the launch of an advanced fibrin sealant Baxter introduced a next-generation fibrin sealant with improved adhesive properties and faster clotting time.

In January 2024, Ethicon (Johnson & Johnson) expanded its hemostatic powder portfolio Ethicon received FDA approval for a new formulation of its hemostatic powder, designed for minimally invasive surgeries.

In November 2023, Integra LifeSciences announced the acquisition of regenerative medicine startup Integra LifeSciences acquired a biotech company specializing in plant-based hemostatic agents.

1 INTRODUCTION OF GLOBAL HEMOSTATS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HEMOSTATS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
4.3 Drivers
4.4 Restraints
4.5 Opportunities
4.6 Porters Five Force Model
4.7 Value Chain Analysis

5 GLOBAL HEMOSTATS MARKET, BY END USER

5.1 Overview
5.2 Clinics
5.3 Hospitals
5.4 Ambulatory Centers

6 GLOBAL HEMOSTATS MARKET, BY PRODUCT

6.1 Overview
6.2 Thrombin-Based Hemostats
6.3 Oxidized Regenerated Cellulose-Based Hemostats
6.4 Collagen-Based Hemostats
6.5 Polysaccharide Hemostats

7 GLOBAL HEMOSTATS MARKET, BY FORMULATION

7.1 Overview
7.2 Matrix & Gel Hemostats
7.3 Sheet & Pad Hemostats
7.4 Powder Hemostats
7.5 Sponge Hemostats

8 GLOBAL HEMOSTATS MARKET, BY APPLICATION

8.1 Overview
8.2 Orthopedic Surgery
8.3 General Surgery
8.4 Neurological Surgery
8.5 Cardiovascular Surgery
8.6 Gynecological Surgery

9 GLOBAL HEMOSTATS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL HEMOSTATS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 CR Bard, Inc
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 B. Braun Melsungen AG
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Baxter International, Inc.
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Integra LifeSciences
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Marine Polymer Technologies, Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Teleflex
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Ethicon, Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Pfizer, Inc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Z-Medica LLC
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Gelita Medical GmbH
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments